Citius Oncology issues new warrants for 25555556 shares after USD 11.5 million exercise

Citius Pharmaceuticals Inc
Tenx Keane Acquisition

Citius Pharmaceuticals Inc

CTXR

0.00

Tenx Keane Acquisition

CTOR

0.00

  • Citius Oncology set immediate exercise of outstanding warrants for 12,777,778 shares at USD 0.9 per share, targeting about USD 11.5 million in gross proceeds; closing expected May 6, 2026.
  • New unregistered warrants to buy 25,555,556 shares to be issued as consideration; exercise price USD 0.9; expiry five years after later of stockholder approval or effectiveness of resale registration statement.
  • Company to issue Avenue warrants for 11,111,111 shares at USD 0.9 in connection with a senior credit facility; additional warrant coverage tied to any future tranche funding.
  • Registration statement to be filed covering resale of shares underlying new warrants.
  • Existing December 2025 warrants for 15,697,024 shares to be amended at closing to cut exercise price to USD 0.9 from USD 1.09; exercisable after stockholder approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.